Cargando…

Valganciclovir is not associated with decreased EBV infection rate in pediatric kidney transplantation

INTRODUCTION: Primary infection or reactivation of Epstein-Barr Virus (EBV) is a significant cause of morbidity and mortality in pediatric kidney transplantation. Valganciclovir (VGC) treatment is recommended for prophylaxis of cytomegalovirus infection, but its role for the prevention of EBV infect...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cheyssac, Elodie, Savadogo, Hamidou, Lagoutte, Nathan, Baudouin, Véronique, Charbit, Marina, Novo, Robert, Sellier-Leclerc, Anne-Laure, Fila, Marc, Decramer, Stéphane, Merieau, Elodie, Zaloszyc, Ariane, Harambat, Jérôme, Roussey, Gwenaelle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pediatrics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9871758/ https://www.ncbi.nlm.nih.gov/pubmed/36704127 http://dx.doi.org/10.3389/fped.2022.1085101

Ejemplares similares

National survey of prevention and management of CMV infection in pediatric kidney transplantation in comparison to clinical practice guidelines
por: Madden, Iona, et al.
Publicado: (2022)

Social Deprivation Is Associated With Lower Access to Pre-emptive Kidney Transplantation and More Urgent-Start Dialysis in the Pediatric Population
por: Driollet, Bénédicte, et al.
Publicado: (2021)

Targeted therapy with nanatinostat and valganciclovir in recurrent EBV-positive lymphoid malignancies: a phase 1b/2 study
por: Haverkos, Bradley, et al.
Publicado: (2023)

Valganciclovir: Leucopenia: case report
Publicado: (2021)

Efficacy and safety of an innovative prolonged-release combination drug in patients with distal renal tubular acidosis: an open-label comparative trial versus standard of care treatments
por: Bertholet-Thomas, Aurélia, et al.
Publicado: (2020)

Safety, efficacy, and acceptability of ADV7103 during 24 months of treatment: an open-label study in pediatric and adult patients with distal renal tubular acidosis
por: Bertholet-Thomas, Aurélia, et al.
Publicado: (2021)

Optimizing COVID-19 Vaccination Strategy in Pediatric Kidney Transplant Recipients: Humoral and Cellular Response to SARS-CoV-2 mRNA Vaccination
por: Nel, Isabelle, et al.
Publicado: (2023)

1564. Lower Rates of Epstein–Barr Virus (EBV) Viremia in Pediatric Solid Organ Transplant (SOT) Recipients Who Received Valganciclovir Prophylaxis
por: Moulton, Elizabeth A, et al.
Publicado: (2018)

Efficacy and safety of intravenous immunoglobulin with rituximab versus rituximab alone in childhood-onset steroid-dependent and frequently relapsing nephrotic syndrome: protocol for a multicentre randomised controlled trial
por: Hogan, Julien, et al.
Publicado: (2020)

Cytomegalovirus retinitis treated with valganciclovir in Wegener’s granulomatosis
por: Kabata, Yoshiaki, et al.
Publicado: (2012)

Valganciclovir as Add-On to Standard Therapy in Secondary Glioblastoma
por: Stragliotto, Giuseppe, et al.
Publicado: (2020)

Mycophenolate-mofetil/valganciclovir: Neutropenia: case report
Publicado: (2022)

Quality of life in adolescents with chronic kidney disease who initiate haemodialysis treatment
por: Clavé, Stéphanie, et al.
Publicado: (2019)

Valganciclovir in the treatment of cytomegalovirus retinitis in HIV-infected patients
por: Patil, A Jayaprakash, et al.
Publicado: (2010)

Development of an appropriate simple suspension method for valganciclovir medication
por: Masaoka, Yasuyuki, et al.
Publicado: (2020)

Characteristics of morbidity and mortality conferences associated with the implementation of patient safety improvement initiatives, an observational study
por: François, Patrice, et al.
Publicado: (2016)

Valganciclovir as Add-on to Second-Line Therapy in Patients with Recurrent Glioblastoma
por: Pantalone, Mattia Russel, et al.
Publicado: (2022)

Chronic Human Herpes Virus 8 Infection Successfully Treated With Valganciclovir
por: Yun, James J, et al.
Publicado: (2009)

New algorithm for valganciclovir dosing in pediatric solid organ transplant recipients
por: Åsberg, A, et al.
Publicado: (2014)

Effects of oral valganciclovir prophylaxis for cytomegalovirus infection in heart transplant patients
por: Doesch, Andreas O, et al.
Publicado: (2012)

High frequency of valganciclovir underdosing for cytomegalovirus prophylaxis after renal transplantation
por: Rissling, Olesja, et al.
Publicado: (2018)

High Throughput Screening of Valganciclovir in Acidic Microenvironments of Polyester Thin Films
por: Schaller, Teilo, et al.
Publicado: (2015)

1146. Thrombocytosis in Infants with Congenital Cytomegalovirus Infection Being Treated with Valganciclovir
por: Murtagh, Kathleen, et al.
Publicado: (2020)

Role of Valganciclovir in Children with Congenital CMV Infection: A Review of the Literature
por: Pata, Davide, et al.
Publicado: (2023)

La place des enfants dans la pandémie et le rôle de la COVID-19 dans leur vie
por: Zaloszyc, Ariane, et al.
Publicado: (2021)

Efficacy of Extended Valganciclovir Prophylaxis in Preventing Cytomegalovirus Infection in Pediatric Kidney Transplantation
por: Hashim, Faris, et al.
Publicado: (2014)

Optimal Use of Ganciclovir and Valganciclovir in Transplanted Patients: How Does It Relate to the Outcome?
por: Mozaffar, Maryam, et al.
Publicado: (2018)

Valganciclovir—Ganciclovir Use and Systematic Therapeutic Drug Monitoring. An Invitation to Antiviral Stewardship
por: Galar, Alicia, et al.
Publicado: (2021)

Assessment of mitochondrial toxicity in newborns and infants with congenital cytomegalovirus infection treated with valganciclovir
por: Ortiz-Gracia, Alba, et al.
Publicado: (2022)

Cytokine and Chemokine Secretome and Risk of CMV Infection Following Discontinuation of Valganciclovir Prophylaxis
por: Fernández-Ruiz, Mario, et al.
Publicado: (2023)

Establishment and Evaluation of a Parametric Population Pharmacokinetic Model Repository for Ganciclovir and Valganciclovir
por: Yang, Wenyu, et al.
Publicado: (2023)

2715. Toxicities and clinical consequences of valganciclovir prophylaxis in solid organ transplant recipients
por: Lahoud, Chloe, et al.
Publicado: (2023)

Assessment of the contribution of morbidity and mortality conferences to quality and safety improvement: a survey of participants’ perceptions
por: Lecoanet, André, et al.
Publicado: (2016)

Treatment of DIHS/DRESS syndrome with combined N-acetylcysteine, prednisone and valganciclovir – a hypothesis
por: Moling, Oswald, et al.
Publicado: (2012)

Lower incidence of CMV infection and acute rejections with valganciclovir prophylaxis in lung transplant recipients
por: Johansson, Inger, et al.
Publicado: (2013)

Efficacy of valganciclovir and ganciclovir for cytomegalovirus disease in solid organ transplants: A meta-analysis
por: Vaziri, Siavash, et al.
Publicado: (2014)

The Association Between Cytomegalovirus Infection and Cardiac Allograft Vasculopathy in the Era of Antiviral Valganciclovir Prophylaxis
por: Klimczak-Tomaniak, Dominika, et al.
Publicado: (2019)

Cytomegalovirus infection can mimic genetic nephrotic syndrome: a case report
por: Hogan, Julien, et al.
Publicado: (2015)

The complex amino acid diet of Francisella in infected macrophages
por: Barel, Monique, et al.
Publicado: (2015)

Pivotal Role of Mitochondria in Macrophage Response to Bacterial Pathogens
por: Ramond, Elodie, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_dsmt56d5ntunqhiorac63uslce